News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZIOPHARM Oncology, Inc. (ZIOP.OB) Presents Safety and Preliminary Efficacy Data from Two Phase I Studies of Indibulin at American Association for Cancer Research Centennial Conference



7/23/2008 9:48:02 AM

MONTEREY, Calif.--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced today that it presented data from two Phase I studies of indibulin, the Company’s novel, orally administered, synthetic tubulin targeted agent, at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine held in Monterey, California, July 20 to 23, 2008.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES